Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Transfusional Iron Overload, Beta-thalassemia
Interventions
SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease
Interventions
disodium EDTA
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami Beach, Florida
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
SPD602
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Orleans, Louisiana • Memphis, Tennessee
Completed Phase 1Phase 2 Interventional Results available

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

NCT04269889
Conditions
Anemia, Diamond-Blackfan
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Mucormycosis
Interventions
deferasirox, Placebo, Liposomal amphotericin B
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 4 more
Conditions
Beta-thalassemia, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis
Industry
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
2 Years to 25 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Gadolinium Deposition Disease
Interventions
Calcium DTPA and Zinc DTPA
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Conditions
Beta-Thalassemia
Interventions
LJPC-401
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
14 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • New York, New York
Conditions
Myelodysplastic Syndromes
Interventions
Deferasirox, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
Conditions
Thalassemia Major
Interventions
DST-0509, Jadenu, Exjade
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
8 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy (TACT)

NCT00044213
Conditions
Coronary Artery Disease
Interventions
EDTA, EDTA Placebo, High Dose Vitamin, High Dose Vitamin Placebo
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
73
States / cities
Little Rock, Arkansas • Danville, California • Fresno, California + 68 more
Conditions
Myelodysplastic Syndromes, Cytopenia
Interventions
Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more
Terminated Phase 3 Interventional Results available

Stroke With Transfusions Changing to Hydroxyurea

NCT00122980
Conditions
Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions
Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transfusion of Older Stored Red Cells

NCT01534676
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Transfusion, Blood, Chelation therapy
Procedure · Biological
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Critical Limb Ischemia, Diabetes
Interventions
Edetate Disodium, Placebo
Drug · Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami Beach, Florida
Conditions
Autism
Interventions
DMSA - dimercaptosuccinic acid
Drug
Lead sponsor
Southwest College of Naturopathic Medicine
Other
Eligibility
3 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Transfusion-dependent Anemia
Interventions
Deferasirox granule formulation, Deferasirox DT formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Oakland, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Myelodysplastic Syndromes, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Conditions
Transfusional Iron Overload in β-thalassemia
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 3 more
Conditions
Toxicity
Interventions
transdermal DMPS
Drug
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona